XPS with Steen Solution Perfusate
Xvivo Perfusion, Inc. · Decision date Apr 26, 2019
What did the FDA approve?
FDA approved the XPS with Steen Solution Perfusate on April 26, 2019, under PMA number P180014. The approval statement describes the device as intended for flushing and temporary continuous normothermic machine perfusion of initially unacceptable excised donor lungs, during which ex vivo function can be reassessed for transplantation.
The applicant is Xvivo Perfusion, Inc., and the device category is a normothermic preservation system for transplantation of initially unacceptable donor lungs. The statement reports the intended use but does not itself provide independent proof of safety or clinical effectiveness. No supplement type or supplement reason is listed, and the source does not describe a relationship to any earlier PMA.
FDA approval order statement
Approval for the XPS with Steen Solution Perfusate. This device is indicated for use in flushing and temporary continuous normothermic machine perfusion of initially unacceptable excised donor lungs during which time the ex vivo function of the lungs can be reassessed for transplantation.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Apr 26, 2019
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P180014
- Regulatory pathway
- Premarket approval application
- Applicant
- Xvivo Perfusion, Inc.
- Product code
- PHO
- Decision code
- APPR
- Decision date
- Apr 26, 2019
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Normothermic preservation system for transplantation of initially unacceptable donor lungs.
- Applicant
- Xvivo Perfusion, Inc.
- Product code
- PHO
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P180014 received
Application receipt date recorded by FDA.
P180014 · FDA decision
APPR
P180014/S014 · Related supplement
XPS with Steen Solution Perfusate
Timeline entries are records held by MedtechLedger for P180014. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P180014
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
XPS with Steen Solution PerfusateP180014/S014 | Xvivo Perfusion, Inc. | PMA supplement | Sep 16, 2026 | FDA |
Explore the linked device profile
Other records with product code PHO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Traferox Technologies, Inc. | PMA supplement | Oct 30, 2026 | FDA | |
| Traferox Technologies, Inc. | PMA supplement | Oct 30, 2026 | FDA | |
LungFX DeviceP240033/S001 | Lung Bioengineering, Inc. | PMA supplement | Oct 16, 2026 | FDA |
LungFX DeviceP240033/S002 | Lung Bioengineering, Inc. | PMA supplement | Oct 16, 2026 | FDA |
TorEx Lung Perfusion SystemP250025 | Traferox Technologies, Inc. | PMA approval | Jul 15, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Xvivo Perfusion, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3666 S Inca St., Englewood, CO, 80110
Sources and methodology
- Original FDA record: P180014
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




